Back to Search Start Over

Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report

Authors :
Jun Osugi
Yuki Owada
Takumi Yamaura
Satoshi Muto
Naoyuki Okabe
Yuki Matsumura
Mitsunori Higuchi
Hiroyuki Suzuki
Mitsukazu Gotoh
Source :
Case Reports in Oncology, Vol 9, Iss 1, Pp 51-55 (2016)
Publication Year :
2016
Publisher :
Karger Publishers, 2016.

Abstract

Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase (ALK) gene rearrangement, is generally well tolerated. In contrast, neutropenia induced by crizotinib is a commonly reported grade 3 or 4 adverse event. In such cases, interruption and dose reduction of crizotinib might be necessary for some patients with severe neutropenia. However, information concerning clinical experience and management of severe neutropenia is currently limited. In this report, the successful management of crizotinib-induced neutropenia by dose reduction of crizotinib in a patient with ALK-positive non-small cell lung cancer is described.

Details

Language :
English
ISSN :
16626575
Volume :
9
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Case Reports in Oncology
Publication Type :
Academic Journal
Accession number :
edsdoj.48d9358043204380944d602ab615e5ad
Document Type :
article
Full Text :
https://doi.org/10.1159/000443662